



(11)

**EP 1 717 246 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**07.10.2015 Bulletin 2015/41**

(45) Date of publication and mention  
of the grant of the patent:  
**12.08.2015 Bulletin 2015/33**

(21) Application number: **05703305.2**

(22) Date of filing: **05.01.2005**

(51) Int Cl.:  
**C07K 14/525** <sup>(2006.01)</sup> **A61K 38/00** <sup>(2006.01)</sup>  
**A61K 47/48** <sup>(2006.01)</sup> **C12N 15/09** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/JP2005/000032**

(87) International publication number:  
**WO 2005/066206 (21.07.2005 Gazette 2005/29)**

(54) **TNF ANTAGONISTS AND TNF INHIBITORS COMPRISING THE SAME AS THE ACTIVE INGREDIENT**

TNF-ANTAGONISTEN UND DIESE ALS WIRKSTOFF ENTHALTENDE TNF-INHIBITOREN

ANTAGONISTES DU TNF, ET INHIBITEURS DU TNF LES CONTENANT EN TANT QU'INGREDIENT ACTIF

(84) Designated Contracting States:  
**DE GB**

(30) Priority: **06.01.2004 JP 2004001427**

(43) Date of publication of application:  
**02.11.2006 Bulletin 2006/44**

(73) Proprietors:  
• **National Institutes of Biomedical Innovation,  
Health and Nutrition  
Osaka 567-0085 (JP)**  
• **Mayumi, Tadanori  
Kobe-shi,  
Hyogo 6512273 (JP)**  
• **Tsutsumi, Yasuo  
Toyono-gun,  
Osaka 563-0105 (JP)**  
• **Nakagawa, Shinsaku  
Yao-shi,  
Osaka 581-0045 (JP)**

(72) Inventors:  
• **MAYUMI, Tadanori  
Nishi-ku, Kobe-shi, Hyogo 6512273 (JP)**

• **TSUTSUMI, Yasuo  
Osaka 5630105 (JP)**  
• **NAKAGAWA, Shinsaku  
Osaka 5810045 (JP)**  
• **OHTA, Tsunetaka  
Okayama-shi, Okayama 7000907 (JP)**

(74) Representative: **Daniels, Jeffrey Nicholas et al  
Page White & Farrer  
Bedford House  
John Street  
London WC1N 2BF (GB)**

(56) References cited:  
**EP-A- 0 486 908 EP-A- 0 563 714**  
**EP-A2- 1 354 893 US-A- 5 606 023**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 717 246 B8**

- |   |   |
|---|---|
| <ul style="list-style-type: none"> <li>• ZHANG X M ET AL: "SITE-DIRECTED MUTATIONAL ANALYSIS OF HUMAN TUMOR NECROSIS FACTOR-ALPHA RECEPTOR BINDING SITE AND STRUCTURE-FUNCTIONAL RELATIONSHIP" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 267, no. 33, 25 November 1992 (1992-11-25), pages 24069-24075, XP002922635 ISSN: 0021-9258</li> <li>• LOETSCHER H. ET AL.: 'Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive especificity for the 55-kDa or 75-kDa TNF receptors.' J. BIOL.CHEM. vol. 268, 1993, pages 26350 - 26357, XP002304715</li> <li>• TSUTSUMI Y. ET AL.: 'Phage hyomen teijiho o kushishita kinosei jinko tanpakushitsu no soshutsu to DDS eno tenkial.' DRUG DELIVERY SYSTEM. vol. 18, 2003, pages 536 - 544, XP002992180</li> </ul> | <ul style="list-style-type: none"> <li>• OSTADE VAN X ET AL: "HUMAN TUMOR NECROSIS FACTOR MUTANTS WITH PREFERENTIAL BINDING TO AND ACTIVITY ON EITHER THE R55 OR R15 RECEPTOR", EUROPEAN JOURNAL OF BIOCHEMISTRY, BLACKWELL PUBLISHING, BERLIN, DE, vol. 3, no. 220, 1 January 1994 (1994-01-01), pages 771-779, XP008003605, ISSN: 0014-2956, DOI: 10.1111/J.1432-1033.1994.TB18678.X</li> </ul> |
|---|---|